反应详情

To a solution of the sodium chloride salt of 3-(5-methylpyridin-2-yl)-5-(2-methylpyrimidin-5-yl)benzoic acid (35 mg, 0.073 mmol) in N,N-dimethylformamide (0.728 mL) was added the hydrochloride salt of (1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethanamine (17.5 mg, 0.087 mmol), EDC (16.8 mg, 0.087 mmol), HOBT (11.2 mg, 0.073 mmol), and triethylamine (0.041 mL, 0.291 mmol). After 16 h, water and trifluoroacetic acid were added. Purification by reverse phase chromatography (C-18, 95% water/acetonitrile→25% water/acetonitrile with 0.1% trifluoroacetic acid) gave the title compound (28.8 mg). HRMS 415.1880 (M+1). 1H NMR (500 MHz, CD3OD): δ 9.21 (s, 2H); 8.78 (s, 1H); 8.57-8.53 (m, 2H); 8.49 (d, J=9.5 Hz, 2H); 8.42 (d, J=8.3 Hz, 1H); 5.51 (q, J=7.2 Hz, 1H); 2.80 (s, 3H); 2.64 (s, 3H); 2.37 (s, 3H); 1.75 (d, J=7.1 Hz, 3H).

1. customPurification by reverse phase chromatography (C-18, 95% water/acetonitrile→25% water/acetonitrile with 0.1% trifluoroacetic acid)